Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold.Kineta was founded in 2008 and is based in Seattle, Washington.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 28, 2022 | Series Unknown | $7.50M | — | — | — | Detail |
| Dec 19, 2022 | IPO | — | — | — | — | Detail |
| Jun 1, 2021 | Corporate Round | $17.39M | 1 |
Cheongbo Industrial Co. (CBI)
|
— | Detail |
| May 5, 2020 | Series Unknown | $5M | 1 |
SCHLAEPFER FAMILY FOUNDATION
|
— | Detail |
| Aug 6, 2019 | Grant | $1.80M | 1 |
Wellcome Trust
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Cheongbo Industrial Co. (CBI)
|
Yes | Corporate Round |
SCHLAEPFER FAMILY FOUNDATION
|
Yes | Series Unknown |
Wellcome Trust
|
Yes | Grant |
SFC Capital
|
Yes | Series Unknown |
Keiretsu Capital
|
Yes | Series B |
Keiretsu Forum
|
— | Series Unknown |
National Institute of Allergy and Infectious Diseases
|
— | Grant |
Keiretsu Forum Northwest
|
— | Series Unknown |
AngelMD
|
— | Funding Round |
RJ Jones
|
— | Series Unknown |
Kineta has acquired 1 organizations. Their most recent acquisition was Kineta (Reverse Merger With Yumanity Therapeutics) on Dec 19, 2022. They acquired Kineta (Reverse Merger With Yumanity Therapeutics) for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Dec 19, 2022
Kineta (Reverse Merger With Yumanity Therapeutics)
|
Biotechnology | merge | — | Detail |